** Shares of Israel-based drug developer Galmed Pharmaceuticals GLMD.O down 5.5% to $1.38
** Maxim Group cuts rating from to "hold" from "buy," and removes PT
** Downgrading GLMD due to the lack of clarity on the path forward and strategic positioning - Maxim
** GLMD may also potentially require a capital raise to commence a clinical trial; under current market conditions, financing will likely be difficult and significantly dilutive, Maxim says
** Up to last close, GLMD had fallen over 52% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.